ÂÜÀòÂÒÂ×

Dr. Matthew Roden is the CEO of HotKnot Therapeutics, an MPM portfolio company. Matt serves on the board of iTeos Therapeutics (NASDAQ: ITOS) and as chairman of the board of Turmeric Acquisition Corp, both MPM portfolio companies.

Prior to joining MPM, Matt’s career spanned senior leadership in large pharma, the healthcare equity capital markets, and in basic science as an immunologist and structural biologist. Most recently, Matt was Senior Vice President and Head of Enterprise Strategy at Bristol Myers Squibb (BMS). In this role, Matt delivered the initial strategic plan for the company following its acquisition of Celgene. Earlier, he served as Head of Strategic Corporate Development, accountable for mergers and acquisitions, structured transactions, strategic equity investing, and divestitures, as well as Head of Global BD Assessment, leading business development search and evaluation activities for all therapeutic categories. Matt served on the R&D Leadership Team representing external innovation and led teams on over 100 business development transactions that are cumulatively valued at over $125 billion, including BMS’ acquisition of Celgene, the largest acquisition in the healthcare industry to date.

Before joining BMS, Matt was Head of Biotechnology Equity Research at UBS Investment Bank. Earlier, he was a Senior Equity Analyst covering biotechnology at J.P. Morgan and Bank of America Merrill Lynch, and was an Associate at Credit Suisse First Boston. In addition to his research coverage of the entire biotech sector, Matt and his teams provided equity research diligences and investor engagement on 24 Initial Public Offerings totaling $3.3bn in initial value from 2005-2016. Matt has also served in advisory or Board capacities to several organizations, including biotechnology companies, investment funds, BIO, BioNJ, and the State of New Jersey.

Matt earned his Ph.D. from the Albert Einstein College of Medicine, focusing on the structural biology of immune-relevant molecules. His graduate work was preceded by his pre-doctoral clinical research fellowship in immuno-oncology at the National Cancer Institute in Bethesda, Maryland. Matt received a M.S. degree from Georgetown University and a B.S. from George Mason University.